VIR - Why did Vir Biotechnology stock drop today?

Vir Biotechnology (VIR -9.0%) the maker of COVID-19 antibody therapy sotrovimab is trading lower for the second consecutive session on Monday. Aside from the general weakness in the market, the recent decline in COVID-19 cases and hospitalizations appeared to have led to the recent selloff.  Vir (NASDAQ:VIR) has lost more than a third of its value so far, while GlaxoSmithKline (GSK -2.2%) its partner for sotrovimab has dropped ~3%. Their rival developers of COVID-19 therapies, Eli Lilly (LLY -1.2%), Regeneron (REGN -0.8%), and Gilead (GILD -1.9%), have also joined today's slump along with several developers of vaccines and pills. Thanks to sales of nearly 1.7M doses to date, Sotrovimab has been a significant driver of growth for Vir (VIR) in recent months. The company recognized $917.3M collaboration revenue linked to the therapy in 2021, making up ~84% of its topline. The partners target to manufacture about 2M doses of Sotrovimab

For further details see:

Why did Vir Biotechnology stock drop today?